Figure 2.
Percent responder on different outcomes according to patient global impression of change/improvement in clinical trials of gabapentin, pregabalin, and duloxetine for diabetic peripheral neuropathy (A) and postherpetic neuralgia (B).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.